Trials Information
For five years now, Daval has been working closely with its industry partners towards refining the Aimspro manufacturing process with a view to obtaining an IMP grade medication complying with the requirements of the 2004 European Community clinical trials regulations. This has recently culminated in the granting of the various certifications necessary for entering the Clinical Trial Authorisation process. This means that the Company is now embarking upon the vital phases where independent clinical specialists are testing Aimspro under double blind, placebo controlled conditions.